Omeros Corporation

Omeros Corporation

Omeros Corporation

Omeros is a Seattlebased biopharmaceutical company committed to discovering, developing, and commercializing smallmolecule and protein therapeutics for largemarket as well as orphan indications targeting inflammation, coagulopathies, and disorders of the
Type
B2c
Founded
1994
Raised
$193M
Follow us
Alexa global traffic share
Latest funding
$68,000,000
Post-IPO equity - 2017
$125,000,000
Post-IPO debt - 2016
CRG L.P.
Team Size
50+
Employees
$68,000,000 Post-IPO equity
Drug Delivery Business

Omeros closes $68m public offering

GeekWire

Omeros looks to raise $70M in stock offering to fuel drug development pipeline

Health
$125,000,000 Post-IPO debt
businesswire

Omeros Announces Completion of Initial Funding under $125 Million Credit Facility | Business Wire